Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-12-06 00:00:00 ET · period of report 2024-12-04 · accession 0001415889-24-028567 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-06 | 2024-12-04+ | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +144.6K | 181.4K | +394% | +$121.5K |
| DM | 2024-12-06 | 2024-12-04+ | SPRY | Chakma Justin | Chief Business Off | S - Sale+OE | $14.11 | -144.6K | 136.4K | -51% | -$2.04M |
| DM | 2024-12-06 | 2024-12-04+ | SPRY | Chakma Justin | Chief Business Off | M - OptEx | $0.00 | -144.6K | 50.0K | -74% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-06 | M | A | 50,000 | $0.84 | 186,380 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-05 | S | D | 49,640 | $14.13 | 136,380 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2024-12-05 | M | A | 49,640 | $0.84 | 186,020 | D | — | — | |
| 4 | Common | Common Stock | 2024-12-04 | S | D | 45,000 | $13.95 | 136,380 | D | — | — | (F1) The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2024-12-06 | S | D | 50,000 | $14.23 | 136,380 | D | — | — | (F3) The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 6 | Common | Common Stock | 2024-12-04 | M | A | 45,000 | $0.84 | 181,380 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-12-04 | M | D | 45,000 | $0.00 | 149,640 | D | $0.84 · — to 2029-07-04 | 45,000 Common Stock | (F4) Immediately exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-12-05 | M | D | 49,640 | $0.00 | 100,000 | D | $0.84 · — to 2029-07-04 | 49,640 Common Stock | (F4) Immediately exercisable. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-12-06 | M | D | 50,000 | $0.00 | 50,000 | D | $0.84 · — to 2029-07-04 | 50,000 Common Stock | (F4) Immediately exercisable. |